M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.
How artificial intelligence is reshaping drug discovery and development.
Model N reported during first-half 2024 that 94 percent of pharma executives are taking steps to prepare their revenue management programs for upcoming regulatory changes, with 44 percent specifically calling out Medicaid as a concern.
Data integrity is an ongoing concern across all R&D organizations, no matter what part of the research lifecycle they’re navigating. These concerns extend beyond the potential for delayed timelines or cost overruns.
How is M&A activity faring in 2024 specifically in the pharma/biopharma sector?
A look at trends impacting biopharma and Simtra’s business model.